Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs

About this episode

Bahija Jallal discusses the future of T-cell engagers and the impact of AI on drug discovery.

November 11, 2025 | What is the next modality to focus on in the next 10 years? For Bahija Jallal, CEO of Immunocore, it would be T-cell engagers. In this episode of The Chain, host Rakesh Dixit speaks with Jallal on the potential advantages of bispecific T-cell engager therapy versus T-cell receptor therapy, biggest anticipated changes in drug discovery and development in the next 10 years, and how AI is going to impact the next generation of scientists. Plus, Jallal shares her experiences a...

People in this episode

Host: Rakesh Dixit

Guest: Bahija Jallal

Topics covered

• T-cell engagers
• drug discovery
• AI in science
• bispecific therapy
• biotechnology

Keywords

• T-cell engagers
• drug development
• AI
• biotechnology
• bispecific therapy

Mentioned in this episode

Organizations: Immunocore

More episodes of The Chain: Protein Engineering Podcast

• Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D · June 9, 2026 · 54 min
• Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating · May 12, 2026 · 47 min
• Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design · April 15, 2026 · 39 min
• Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement · March 17, 2026 · 59 min
• Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies? · February 10, 2026 · 49 min
• Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research · January 13, 2026 · 44 min